Katherine A. High
Affiliations: | Cell and Molecular Biology | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Immunology, Cell Biology, Molecular BiologyWebsite:
http://www.med.upenn.edu/apps/faculty/index.php/g275/p12112Google:
"Katherine High"Children
Sign in to add trainee| Hojun Li | grad student | 2011 | Penn |
| George J. Buchlis | grad student | 2013 | Penn |
| Roland W. Herzog | post-doc | 2000 | Penn (Microtree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| High KA. (2023) THE JEREMIAH METZGER LECTURE: TURNING GENES INTO MEDICINES: HIGHLIGHTS AND HURDLES IN THE DEVELOPMENT OF GENE THERAPY FOR GENETIC DISEASE. Transactions of the American Clinical and Climatological Association. 133: 204-233 |
| Elkouby L, Armour SM, Toso R, et al. (2022) Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A. Molecular Therapy. Methods & Clinical Development. 24: 20-29 |
| George LA, Monahan PE, Eyster ME, et al. (2021) Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. The New England Journal of Medicine. 385: 1961-1973 |
| Zou C, Vercauteren KOA, Michailidis E, et al. (2020) Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice. Molecular Therapy. Methods & Clinical Development. 18: 189-198 |
| George LA, Ragni MV, Rasko JEJ, et al. (2020) Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Xiang Z, Kurupati RK, Li Y, et al. (2019) The Effect of CpG Sequences on Capsid-Specific CD8 T Cell Responses to AAV Vector Gene Transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Maguire AM, Russell S, Wellman JA, et al. (2019) Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology. 126: 1273-1285 |
| George LA, Sullivan SK, Rasko JEJ, et al. (2019) Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year Blood. 134: 3347-3347 |
| Drack AV, Bennett J, Russell S, et al. (2019) How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease Journal of Aapos. 23 |
| Anguela XM, High KA. (2018) Entering the Modern Era of Gene Therapy. Annual Review of Medicine |